论文部分内容阅读
引言巴金森氏综合征基本上是一种年迈人的疾病,50岁以前发病率很低,50～59岁时发病率为25/十万人,70岁以上时即增加到超过2000/十万人或为总人口的2%.然而巴金森氏病的现代药物治疗,包括药物的选择、开始治疗的方式,以及维持量等,都只是在较年轻的病人中试用而订.根据这些试验,左旋多巴按大剂量开始(0.5～1gm)、大剂量递增以及大剂量维持(3～8gm)却没有考虑年令(表1).但是很多老年病学家从临床经验中意识到对年纪很老的巴金森氏综合征患者的治疗在方法上与对较年轻病人组的建议需要有很大的不同.对老年组的临床试验证明了这点.
Introduction Parkinson’s disease is basically a disease of the elderly, before the age of 50 the incidence is very low, the incidence of 25 to 100 000 people aged 50 to 59, 70 years of age or more that is increased to over 2000 / 100,000 Or 2% of the population However, modern pharmacological treatment for Parkinson’s disease, including the choice of medication, the way it was started, and the amount of maintenance, were only tried out in younger patients and based on these tests, Levodopa started with a high dose (0.5 ~ 1gm), high dose escalation and high dose maintenance (3 ~ 8gm) did not consider the year (Table 1), but many geriatricians from clinical experience are aware of very old The treatment of older patients with Parkinson’s disease is methodologically different from the recommendations for the younger patient group, as evidenced by clinical trials in the elderly group.